Pacira Pharmaceuticals, Inc.

10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560


Company Overview

Webcast ImageWebcast
Pacira Pharmaceuticals, Inc. Analyst & Investor Day (Replay)
01/22/15 at 4:00 p.m. ET
Pacira Pharmaceuticals, Inc. Analyst & Investor Day
Thursday, January 22, 2015 4:00 p.m. ET  through Thursday, January 22, 2015 
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
              • Dial-in: 1-866-270-6057 (domestic) or 1-617-213-8891 (international)
              • Conference Passcode: 99068919
Corporate Profile
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers.
Stock Quote
PCRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 6.13 (6.10%)
Data as of 01/23/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
01/08/15Pacira Pharmaceuticals, Inc. to Host Analyst & Investor Day on Jan. 22 in New York
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 8, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it has scheduled an Analyst & Investor Day on Thursday, Jan. 22, 2015, from approximately 4:00 to 6:30 p.m. ET in New York. Members of the Pacira management team, along with clinical experts, will provide an overview of the Company’s future expansion plans for additional EXPAREL® indications, as well as the leading DepoFoam®-based... 
Printer Friendly Version
01/08/15Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue of $61.8 Million and Estimated Full-Year Total Revenue of $197.7 Million
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 8, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided its unaudited EXPAREL® and total revenue estimates for the fourth quarter and full-year 2014. “We are pleased with the continued success of EXPAREL in the fourth quarter, growth over the previous quarter and growth for the year, which we expect to provide the basis of a strong 2015,” said Dave Stack, president, chief executiv... 
Printer Friendly Version
12/12/14Pacira Pharmaceuticals Inc. Announces Changes to EXPAREL® Label
PARSIPPANY, N.J.--(BUSINESS WIRE)--Dec. 12, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the U.S. Food and Drug Administration’s (FDA) approval of changes to the EXPAREL packaging and label proposed by the Company as part of a routine label supplement application, submitted on November 27, 2013. The approved label changes are limited to revisions pertaining to the product’s storage, instructions of use and use in special popu... 
Printer Friendly Version
11/25/14Pacira Pharmaceuticals, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 25, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014, at 8:30 a.m. ET in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira... 
Printer Friendly Version

Corporate Presentation

Analyst Day Presentation
Corporate Presentation
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Pacira Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Contact Investor Relations:
Jessica Cho
(973) 254-3574